It is also becoming increasingly clear that NOXA can significantly influence the response of cancer cells to drug therapies, particularly BH3 mimetics such as venetoclax, as NOXA loss has been found to underpin resistance to these agents in lymphoid malignancies [51–53]. This evidence concerns the gene PMAIP1 and cancer.